Clinical outcomes of recombinant human endostatin combined with chemotherapy in the treatment of patients with advanced colorectal cancer

Tumor

Volumn 30, Issue 12, 2010, Pages 1065-1068

  Fan, Cui Zhen ^a   Dai, Hong ^a   Chu, Yu Ping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Clinical outcomes; Colorectal neoplasms; Drug therapy; Recombinant human vascular endostatin

Indexed keywords

CAPECITABINE; IRINOTECAN; RECOMBINANT ENDOSTATIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 78751698626     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2010.12.014     Document Type: Article

References (14)

1. KOOPMAN M, ANTONINI N F, DOUMA J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatinin advanced colorectal cancer (CAIRO): a phase III randomised controlled trial [J]. Ann Oncol, 2006, 17(10): 1523-1528.
2. CHUA Y J, CUNNINGHAM D. Emerging therapies for rectal cancer [J]. Colorectal Dis, 2006, 8(Suppl 3): 18-20.
3. CUNNINGHAM D, HUMBLET Y, SIENA S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351 (4): 337-345.
4. ARDAVANIS A, KOUNTOURAKIS P, MANTZARIS I, et al. Bevacizumab added to their inotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen [J]. Anticancer Res, 2008, 28(5B): 3087-3092.
5. KIRSCH M, SCHACKERT G, BLACK P M. Metastasis and angiogenesis [J]. Cancer Treat Res, 2004, 117: 285-304.
6. FOLKMAN J. Anti-angiogenesis in cancer therapy - endostatin and its mechanisms of action [J]. Expt Cell Res, 2006, 312: 594-407.
7. ABDOLLAHI A, HLATKY L, HUBER P E. Endostatin: the logic of antiangiogenic therapy [J]. Drug Resist Udat, 2005, 8(122): 59-74.
8. PATT Y Z, LEE F C, LIEBMANN J E, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy far metastatic colorectal cancer [J]. Am J Clin Oncol, 2007, 30 (4): 350-357.
9. FOLKMAN J. Antiangiogenesis in cancer therapy endostatin and its mechanisms of action [J]. Exp Cell Res, 2006, 312(5): 594-607.
10. SUN L, YE H Y, ZHANG Y H, et al. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection [J]. World J Gastroenterol, 2007, 13(45): 6115-6118.
11. KERKELÄ R, GRAZETTE L, YACOBI R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate [J]. Nat Med, 2006, 12(8): 908-916.